XTL Biopharmaceuticals Ltd. (XTLB)

USD 1.49

(-3.61%)

Market Cap (In USD)

18.73 Million

Revenue (In USD)

-

Net Income (In USD)

-1.78 Million

Avg. Volume

10.84 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.76-4.99
PE
-
EPS
-
Beta Value
0.996
ISIN
US98386D3070
CUSIP
98386D307
CIK
1023549
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Shlomo Spokone Shalev
Employee Count
-
Website
https://www.xtlbio.com
Ipo Date
2005-09-01
Details
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.